Leerink Partnrs Has Positive Forecast for SRPT Q3 Earnings

Key Points

• Leerink Partners has revised its Q3 2026 earnings per share estimate for Sarepta Therapeutics upward to $2.20, reflecting increased optimism about the company's financial performance.
• The company's most recent quarterly earnings report showed a significant increase in revenue, which rose by 68.4% year-over-year, leading to an earnings per share of $2.02, exceeding analysts' expectations.
• Overall, the stock currently holds a consensus rating of "Hold", with eight analysts recommending a Buy and others divided between Hold and Sell ratings.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Leerink Partnrs upped their Q3 2026 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, September 8th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will earn $2.20 per share for the quarter, up from their previous forecast of $2.07. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. During the same period in the prior year, the business posted $0.07 earnings per share. Sarepta Therapeutics's revenue was up 68.4% compared to the same quarter last year.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. upgraded shares of Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 price objective on the stock in a report on Tuesday, July 29th. HC Wainwright reiterated a "sell" rating on shares of Sarepta Therapeutics in a report on Monday, August 25th. Needham & Company LLC reiterated an "underperform" rating on shares of Sarepta Therapeutics in a report on Monday, July 28th. Wells Fargo & Company increased their target price on shares of Sarepta Therapeutics from $48.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Finally, Oppenheimer upgraded shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $30.00 to $37.00 in a report on Tuesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $42.36.

Sarepta Therapeutics Trading Down 2.9%

NASDAQ SRPT traded down $0.52 during trading hours on Wednesday, hitting $17.39. The company's stock had a trading volume of 3,492,616 shares, compared to its average volume of 7,880,755. The stock has a fifty day moving average of $17.75 and a 200 day moving average of $41.28. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $138.81. The firm has a market capitalization of $1.70 billion, a P/E ratio of -19.99 and a beta of 0.49. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Thrivent Financial for Lutherans grew its position in Sarepta Therapeutics by 3.3% in the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company's stock valued at $396,000 after purchasing an additional 744 shares in the last quarter. FORA Capital LLC grew its position in shares of Sarepta Therapeutics by 1,442.4% in the 2nd quarter. FORA Capital LLC now owns 93,189 shares of the biotechnology company's stock valued at $1,594,000 after acquiring an additional 87,147 shares during the period. CANADA LIFE ASSURANCE Co grew its position in shares of Sarepta Therapeutics by 2.5% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 71,533 shares of the biotechnology company's stock valued at $1,224,000 after acquiring an additional 1,769 shares during the period. Corient Private Wealth LLC grew its position in shares of Sarepta Therapeutics by 75.0% in the 2nd quarter. Corient Private Wealth LLC now owns 12,530 shares of the biotechnology company's stock valued at $214,000 after acquiring an additional 5,371 shares during the period. Finally, E Fund Management Co. Ltd. grew its position in shares of Sarepta Therapeutics by 81.4% in the 2nd quarter. E Fund Management Co. Ltd. now owns 16,525 shares of the biotechnology company's stock valued at $283,000 after acquiring an additional 7,416 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.